Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin.
The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Aradigm lands NIH grant for inhaled, liposomal products appeared first on MassDevice.
from MassDevice http://ift.tt/2x0TRbW
Cap comentari:
Publica un comentari a l'entrada